Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
EW logo EW
Upturn stock ratingUpturn stock rating
EW logo

Edwards Lifesciences Corp (EW)

Upturn stock ratingUpturn stock rating
$78.18
Last Close (24-hour delay)
Profit since last BUY4.35%
upturn advisory
Consider higher Upturn Star rating
BUY since 70 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: EW (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

32 Analysts rated it

Highly popular stock, broad analyst coverage, trusted insights, strong investor interest.

1 Year Target Price $87.52

1 Year Target Price $87.52

Analysts Price Target For last 52 week
$87.52 Target price
52w Low $64.01
Current$78.18
52w High $83

Analysis of Past Performance

Type Stock
Historic Profit -1.48%
Avg. Invested days 44
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 45.95B USD
Price to earnings Ratio 32.74
1Y Target Price 87.52
Price to earnings Ratio 32.74
1Y Target Price 87.52
Volume (30-day avg) 32
Beta 1.08
52 Weeks Range 64.01 - 83.00
Updated Date 08/15/2025
52 Weeks Range 64.01 - 83.00
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) 2.39

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2025-07-22
When Before Market
Estimate 0.6231
Actual 0.67

Profitability

Profit Margin 72.96%
Operating Margin (TTM) 28.12%

Management Effectiveness

Return on Assets (TTM) 8.42%
Return on Equity (TTM) 15.53%

Valuation

Trailing PE 32.74
Forward PE 31.55
Enterprise Value 42539878000
Price to Sales(TTM) 8.08
Enterprise Value 42539878000
Price to Sales(TTM) 8.08
Enterprise Value to Revenue 7.48
Enterprise Value to EBITDA 23.27
Shares Outstanding 587100032
Shares Floating 581046999
Shares Outstanding 587100032
Shares Floating 581046999
Percent Insiders 0.91
Percent Institutions 88.28

ai summary icon Upturn AI SWOT

Edwards Lifesciences Corp

stock logo

Company Overview

overview logo History and Background

Edwards Lifesciences was founded in 1958 by Miles "Lowell" Edwards and Albert Starr. Initially focused on heart valve replacement, it pioneered the first commercially available artificial heart valve. The company has evolved into a global leader in patient-focused medical innovations for structural heart disease and critical care monitoring.

business area logo Core Business Areas

  • Transcatheter Aortic Valve Replacement (TAVR): This segment focuses on minimally invasive heart valve replacement through a catheter, primarily for aortic stenosis. It's their largest revenue driver.
  • Surgical Structural Heart: This segment offers surgical heart valve repair and replacement products, including tissue and mechanical valves, as well as annuloplasty rings and other surgical structural heart therapies.
  • Critical Care: This segment provides hemodynamic monitoring systems used in intensive care units to measure a patient's cardiac function and fluid status.
  • Transcatheter Mitral and Tricuspid Therapies (TMTT): This is an emerging segment focused on developing minimally invasive solutions for mitral and tricuspid valve diseases.

leadership logo Leadership and Structure

Edwards Lifesciences is led by CEO Bernard Zovighian. The company has a traditional corporate structure with functional departments like R&D, Sales, Marketing, Operations, and Finance. It also has regional teams focused on specific geographic markets.

Top Products and Market Share

overview logo Key Offerings

  • SAPIEN TAVR Valves: Edwards' SAPIEN family of TAVR valves are the market leader in the transcatheter aortic valve replacement space. Estimated market share is around 50%. Competitors include Medtronic (MDT) and Boston Scientific (BSX). High margin product line and a major revenue generator.
  • Inspiris Resilia Aortic Valve: This surgical aortic valve is designed for durability and provides patients with potentially longer-lasting valve replacement options. Competitors include Medtronic (MDT) and Abbott (ABT).
  • Swan-Ganz Catheters: These catheters are used for advanced hemodynamic monitoring in critically ill patients. They provide real-time data on cardiac output and other vital parameters. Main competitor is ICU Medical (ICUI).

Market Dynamics

industry overview logo Industry Overview

The medical device industry is characterized by innovation, regulation, and demographic shifts (aging population). The structural heart market is growing rapidly due to the increasing prevalence of heart valve disease and the preference for minimally invasive procedures.

Positioning

Edwards Lifesciences is a leader in the structural heart disease market, particularly in TAVR. Its competitive advantages include its strong brand reputation, extensive clinical data supporting its products, and robust R&D pipeline.

Total Addressable Market (TAM)

The global structural heart market is estimated to be worth over $20 billion. Edwards is well-positioned to capture a significant portion of this market due to its leadership in TAVR and expanding portfolio in TMTT.

Upturn SWOT Analysis

Strengths

  • Market leader in TAVR
  • Strong brand reputation
  • Extensive clinical data
  • Robust R&D pipeline
  • Global presence

Weaknesses

  • High reliance on TAVR market
  • Relatively higher price points compared to competitors
  • Potential for increased competition
  • Exposure to regulatory changes

Opportunities

  • Expansion into emerging markets
  • Growth in TMTT market
  • Development of new technologies and therapies
  • Partnerships and acquisitions

Threats

  • Increased competition from existing and new players
  • Pricing pressures from healthcare providers and payers
  • Adverse regulatory changes
  • Product liability lawsuits

Competitors and Market Share

competitor logo Key Competitors

  • MDT
  • BSX
  • ABT
  • SYK

Competitive Landscape

Edwards has a strong lead in TAVR with SAPIEN valves, known for robust clinical data and ease of use. Medtronic poses a significant threat with its Evolut platform. Boston Scientific and Abbott are also competing for market share, creating pricing pressures.

Major Acquisitions

Harpoon Medical

  • Year: 2017
  • Acquisition Price (USD millions): 250
  • Strategic Rationale: Harpoon Medicalu2019s investigational device for minimally invasive surgical repair of the mitral valve was acquired to expand Edward's portfolio of mitral valve therapies.

Growth Trajectory and Initiatives

Historical Growth: Edwards Lifesciences has experienced strong revenue growth in recent years, primarily driven by the adoption of TAVR technology. Their growth is expected to continue but at a slightly lower rate.

Future Projections: Analysts project continued growth for Edwards Lifesciences, driven by TAVR, TMTT and the overall increase in cardiovascular disease as the population ages.

Recent Initiatives: Recent initiatives include expanding the indications for TAVR, investing in TMTT research and development, and expanding its presence in emerging markets.

Summary

Edwards Lifesciences is a strong company with a dominant position in the growing TAVR market. Its robust R&D pipeline and investments in TMTT position it well for future growth. However, increasing competition and pricing pressures remain key challenges. Continued innovation and expansion into new markets will be crucial for sustaining its long-term success.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Investor Relations
  • SEC Filings (10K, 10Q)
  • Industry Reports
  • Analyst Estimates

Disclaimers:

The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data are estimates and may vary.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Edwards Lifesciences Corp

Exchange NYSE
Headquaters Irvine, CA, United States
IPO Launch date 2000-03-27
CEO & Director Mr. Bernard J. Zovighian
Sector Healthcare
Industry Medical Devices
Full time employees 15800
Full time employees 15800

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. The company offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband brands. It also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.